Correlation of Glypican-4 Level with Basal Active Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes Mellitus.
10.3803/EnM.2016.31.3.439
- Author:
Sang Ah LEE
1
;
Gwanpyo KOH
;
Suk Ju CHO
;
So Yeon YOO
;
Sang Ouk CHIN
Author Information
1. Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea. salee@jejunu.ac.kr
- Publication Type:Original Article
- Keywords:
Glypicans;
Active glucagon-like peptide 1;
Diabetes mellitus
- MeSH:
Adipocytes;
Aprotinin;
Aspartate Aminotransferases;
Body Mass Index;
Diabetes Mellitus;
Diabetes Mellitus, Type 2*;
Gastric Inhibitory Polypeptide;
Glucagon-Like Peptide 1*;
Glypicans*;
Hemoglobin A, Glycosylated;
Humans;
Insulin;
Insulin Resistance;
Linear Models;
Multivariate Analysis;
Plasma;
Receptor, Insulin
- From:Endocrinology and Metabolism
2016;31(3):439-445
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Previous studies have reported that glypican-4 (GPC4) regulates insulin signaling by interacting with insulin receptor and through adipocyte differentiation. However, GPC4 has not been studied with regard to its effects on clinical factors in patients with type 2 diabetes mellitus (T2DM). We aimed to identify factors associated with GPC4 level in T2DM. METHODS: Between January 2010 and December 2013, we selected 152 subjects with T2DM and collected serum and plasma into tubes pretreated with aprotinin and dipeptidyl peptidase-4 inhibitor to preserve active gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). GPC4, active GLP-1, active GIP, and other factors were measured in these plasma samples. We performed a linear regression analysis to identify factors associated with GPC4 level. RESULTS: The subjects had a mean age of 58.1 years, were mildly obese (mean body mass index [BMI], 26.1 kg/m2), had T2DM of long-duration (mean, 101.3 months), glycated hemoglobin 7.5%, low insulin secretion, and low insulin resistance (mean homeostatic model assessment of insulin resistance [HOMA-IR], 1.2). Their mean GPC4 was 2.0±0.2 ng/mL. In multivariate analysis, GPC4 was independently associated with age (β=0.224, P=0.009), and levels of active GLP-1 (β=0.171, P=0.049) and aspartate aminotransferase (AST; β=–0.176, P=0.043) after being adjusted for other clinical factors. CONCLUSION: GPC4 was independently associated with age, active GLP-1, and AST in T2DM patients, but was not associated with HOMA-IR and BMI, which are well known factors related to GPC4. Further study is needed to identify the mechanisms of the association between GPC4 and basal active GLP-1 levels.
